Clinical trial
Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
NCT00391274 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00391274 |
|---|---|
| Title | Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC) |
| Official title | Phase 3 Study of Pemetrexed Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed, docetaxel |
| Enrollment | 211 |
| Start date | Oct 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Jun 1, 2010 |
| First posted | Oct 23, 2006 |
| Last update posted | Apr 12, 2011 |
| Countries | China |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: